PTX3 was able to differentiate liver cancer patients from healthy control subjects with an AUC of 0.734, a sensitivity of 73.24%, and a specificity of 84.78% (95% CI: 0.531–0.892) (Table 3 and Fig. 3). Here, PTX3 is linked to liver cancer.